IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
+3.55%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$349M
AUM Growth
+$349M
(-20%)
Cap. Flow
-$46.8M
Cap. Flow
% of AUM
-13.39%
Top 10 Holdings %
Top 10 Hldgs %
42.96%
Holding
198
New
27
Increased
9
Reduced
43
Closed
22
Top Buys
Top Sells
| 1 |
Apellis Pharmaceuticals
APLS
|
$11.5M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$7.89M |
| 3 |
CMPS
Compass Pathways
CMPS
|
$6.85M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
$6.66M |
| 5 |
Xenon Pharmaceuticals
XENE
|
$6.2M |
Sector Composition
| 1 | Healthcare | 97.67% |
| 2 | Consumer Staples | 0.57% |
| 3 | Technology | 0.35% |
| 4 | Financials | 0.21% |
| 5 | Real Estate | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
iShares Biotechnology ETF
IBB
$5.68B
| $3.67M | 0.55% |
+24,022
| New | +$3.67M |
|
27
Iovance Biotherapeutics
IOVA
$800M
| $3.29M | 0.49% |
172,521
| – | – |
|
|
FNCH
28
DELISTED
Finch Therapeutics Group, Inc. Common Stock
FNCH
| $3.15M | 0.47% |
315,732
| – | – |
|
29
Wave Life Sciences
WVE
$1.27B
| $3.12M | 0.46% |
993,481
| – | – |
|
|
CLVS
30
DELISTED
Clovis Oncology, Inc.
CLVS
| $3.02M | 0.45% |
1,112,669
| – | – |
|
|
STSA
31
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
| $2.83M | 0.42% |
629,384
| – | – |
|
|
AUTL
32
Autolus Therapeutics
AUTL
$383M
| $2.83M | 0.42% |
544,819
| – | – |
|
|
RCOR
33
DELISTED
Renovacor, Inc.
RCOR
| $2.64M | 0.39% |
342,902
-100,000
| -23% | -$770K |
|
34
MacroGenics
MGNX
$121M
| $2.51M | 0.37% |
156,047
-32,431
| -17% | -$521K |
|
35
Viking Therapeutics
VKTX
$3.02B
| $2.3M | 0.34% |
500,642
| – | – |
|
36
Ovid Therapeutics
OVID
$94.6M
| $2.26M | 0.34% |
705,082
-400,000
| -36% | -$1.28M |
|
37
Madrigal Pharmaceuticals
MDGL
$9.7B
| $2.01M | 0.3% |
23,700
| – | – |
|
38
Clene
CLNN
$55.8M
| $2.01M | 0.3% |
489,321
| – | – |
|
39
TG Therapeutics
TGTX
$5.03B
| $1.91M | 0.29% |
+100,739
| New | +$1.91M |
|
40
Savara
SVRA
$591M
| $1.91M | 0.28% |
1,539,691
| – | – |
|
41
Amicus Therapeutics
FOLD
$2.42B
| $1.9M | 0.28% |
164,174
-250,000
| -60% | -$2.89M |
|
42
Protara Therapeutics
TARA
$125M
| $1.89M | 0.28% |
279,256
-200,739
| -42% | -$1.36M |
|
43
Aurinia Pharmaceuticals
AUPH
$1.58B
| $1.88M | 0.28% |
+82,335
| New | +$1.88M |
|
|
CMMB
44
Chemomab Therapeutics
CMMB
$15.7M
| $1.83M | 0.27% |
265,264
-20,000
| -7% | -$138K |
|
|
ODT
45
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $1.81M | 0.27% |
1,340,631
-500,000
| -27% | -$675K |
|
46
Lyra Therapeutics
LYRA
$11.8M
| $1.72M | 0.26% |
394,536
-8,914
| -2% | -$38.8K |
|
47
Nuvation Bio
NUVB
$1.08B
| $1.7M | 0.25% |
+200,000
| New | +$1.7M |
|
48
Merus
MRUS
$5.04B
| $1.62M | 0.24% |
50,907
| – | – |
|
49
Liquidia Corp
LQDA
$2.52B
| $1.58M | 0.24% |
325,445
-559,448
| -63% | -$2.72M |
|
50
InflaRx
IFRX
$117M
| $1.58M | 0.23% |
331,048
-300,000
| -48% | -$1.43M |
|